



Memorandum of Understanding between EFLM and EPMA

This MoU is due for review on 1st January 2015 with a two year renewal cycle. The effective start is when the document is validated by both Presidents' signatures.



This document has been prepared to define a collaborative working relationship between EFLM (European Federation of Clinical Chemistry and Laboratory Medicine) and EPMA (The European Association for Predictive, Preventive & Personalized Medicine). The organizations enter into this agreement to foster their cooperation and to advance clinical laboratory medicine.

EFLM is the primary federation of European societies of clinical chemistry and laboratory medicine. It creates a platform for all specialists working in the field in Europe. It provides European leadership in clinical chemistry and laboratory medicine to national professional societies, to the diagnostics industry and to governmental and non-governmental organizations to serve the public interest in health care. EFLM's current membership consists of the societies in 39 European countries.

EPMA is the European Association for Predictive, Preventive and Personalised Medicine (PPPM), <http://www.epmanet.eu/>. PPPM is the new integrative concept in healthcare that enables to predict individual predisposition before onset of the disease, to provide targeted preventive measures and create personalised treatment algorithms tailored to the person. The expected outcomes are conducive to more effective population screening, targeted prevention, identification of persons at-risk, stratification of patients for the optimal therapy planning, prediction and reduction of adverse drug-drug or drug-disease interactions relying on emerging technologies, etc. Integrative approach by PPPM is considered as the medicine of the future. Being at the forefront of the global efforts, the EPMA promotes the integrative concept of PPPM among healthcare stakeholders, governmental institutions, educators, funding bodies, patient organisations and in the public domain in altogether 44 countries worldwide, where the Association is represented.

In furtherance of their mutual interest in advancing the health care paradigm from reactive to predictive, preventive and personalized medicine and in laboratory medicine as the integrating element in PPPM, the two organizations agree as follows:

1. The two organizations agree to cooperate and collaborate on programs and activities of mutual interest.
2. EFLM and EPMA recognize the added value of working together to foster cooperation and to advance laboratory medicine. To formalize this cooperation we agree to initiate the establishment of the joint Working Group (WG). The terms of office, terms of reference and WG membership shall be determined in follow-up steps by both parties.
3. The representatives of EFLM and EPMA will endeavor to meet once a year to discuss issues of mutual interest; this may be by conference call.
4. This agreement should be evaluated each year by the senior leadership of each organization. Either party may terminate this agreement with 90 days written notice to the other party.

| | | | |
|--|---|------------------------------|---|
| Date: | September 19 th 2013 | Venue: | EU-Parliament, Brussels |
| Vincenzo Costigliola EPMA President |  | Ian Watson EFLM President |  |